C4 Therapeutics (CCCC) EPS (Weighted Average and Diluted): 2021-2025
Historic EPS (Weighted Average and Diluted) for C4 Therapeutics (CCCC) over the last 5 years, with Sep 2025 value amounting to -$0.44.
- C4 Therapeutics' EPS (Weighted Average and Diluted) fell 25.71% to -$0.44 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.67, marking a year-over-year increase of 1.76%. This contributed to the annual value of -$1.52 for FY2024, which is 43.07% up from last year.
- According to the latest figures from Q3 2025, C4 Therapeutics' EPS (Weighted Average and Diluted) is -$0.44, which was down 18.92% from -$0.37 recorded in Q2 2025.
- C4 Therapeutics' 5-year EPS (Weighted Average and Diluted) high stood at -$0.26 for Q2 2024, and its period low was -$0.76 during Q4 2022.
- In the last 3 years, C4 Therapeutics' EPS (Weighted Average and Diluted) had a median value of -$0.44 in 2025 and averaged -$0.49.
- Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first slumped by 145.16% in 2022, then surged by 64.38% in 2024.
- C4 Therapeutics' EPS (Weighted Average and Diluted) (Quarterly) stood at -$0.31 in 2021, then tumbled by 145.16% to -$0.76 in 2022, then rose by 10.53% to -$0.68 in 2023, then climbed by 27.94% to -$0.49 in 2024, then declined by 25.71% to -$0.44 in 2025.
- Its EPS (Weighted Average and Diluted) stands at -$0.44 for Q3 2025, versus -$0.37 for Q2 2025 and -$0.37 for Q1 2025.